Major Shareholder Atlas Venture Files to Sell Another $1.17M in Korro Bio Stock
KRRO has more than doubled off its 52-week low of $5.204 on elevated volume (1.8× avg).
Summary
Atlas Venture, a major shareholder, has filed to sell an additional $1.17 million of Korro Bio stock, continuing a trend of recent dispositions by the fund.
Key Events · Ownership and Investor Activity · KRRO
-
Intent to Sell Additional Shares
Atlas Venture Fund XI, L.P. filed a Form 144 to sell 85,955 shares of common stock, valued at approximately $1.17 million, with an approximate sale date of July 2, 2026.
-
Ongoing Shareholder Distribution
This proposed sale by Atlas Venture follows previous sales totaling $2.50 million (174,265 shares) by Atlas Venture funds over the past three months, indicating a continued reduction in their holdings.
-
Institutional Investor Liquidation
As a major institutional shareholder, Atlas Venture's repeated filings to sell shares suggest a strategic reduction of its position, which can create selling pressure and investor uncertainty.
Analysis · KRRO · Life Sciences
Atlas Venture, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell an additional $1.17 million worth of Korro Bio common stock. This follows a pattern of recent sales by the fund, totaling nearly $2.5 million in the past three months, and suggests a continued reduction in its stake. While not an immediate sale, this filing creates an overhang on the stock as a major investor signals further liquidation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRRO was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.9M. The 52-week trading range was $5.20 to $55.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.